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HealtH economics evaluation for insulin injection Pen-neeDle witH 
Different lengtHs in Patients witH DiaBetes in cHina
Sun L., Ren X., Zhu S., Liu Y., Chen Y., Sun J., Chen B., Sun S., Wang R.
Shenyang Pharmaceutical University, Shenyang, China
Objectives: To perform a health economics evaluation for insulin injection pen-
needle with different lengths in diabetic patients in China. MethOds: With the 
relationship between HbA1C level and diabetes-related complications obtained from 
literature, cost-benefit analysis was applied to evaluate the net cost saving (includ-
ing the cost of needles and cost of complications and adverse events treatment) of 
shorter pen-needle compared to the longer one, from the perspective of society. The 
unit costs were retrieved from published sources and outcomes of the effectiveness 
were derived from meta-analysis of relevant literatures related to different lengths 
insulin pen-needle. One-way sensitivity analysis was conducted to demonstrate the 
robustness of results. Results: The meta-analysis showed that compared to the 
longer needle, the shorter one decreased HbA1C by an average of 0.11% and reduced 
the risk of hypoglycaemic events by 17%. A net saving of $27 per patient based on 
shorter needle resulted from decreased adverse events, while the costs of needles 
were increased by $9 during the trial time. If the retinopathy was included, shorter 
needle produced a net saving of $320 per patient due to decreased complications, 
and the economic evaluation revealed shorter needle can totally save $338 per 
patient compared to the longer one. If without retinopathy, the net saving was $129 
per patient due to decreased complications, and the totally saving was $147 per 
patient. Sensitivity analysis showed that the results were stable. cOnclusiOns: 
Current findings indicate that shorter insulin injection pen-needle lead to a decreas-
ing of complications and adverse reaction compared to longer needle, and subse-
quently could lead to a reduction in health costs.
PDB61
BurDen of non-aDHerence to tyPe 1 DiaBetes mellitus tHeraPeutic 
guiDelines in france
Beaudet A., Ong R.C.
IMS Health, Basel, Switzerland
Objectives: To investigate the burden of type 1 diabetes mellitus (T1DM) in France 
associated with non-adherence to clinical guidelines using the IMS CORE Diabetes 
Model (CDM) and clinical data from the IMS Lifelink Diabetes Cohort. MethOds: 
The CDM is a health economic model based on 17 inter-dependent sub-models 
that simulate micro- and macrovascular complications associated with diabetes. 
Physiological parameter inputs such as HbA1c, blood lipids, body mass index (BMI), 
and systolic blood pressure (SBP) were taken from real-life data and compared with 
guidelines from the “Haute Autorité de Santé”. T1DM patients (age ≥ 18) who visited 
a general physician between May 2011 and May 2014 and have received at least 
one insulin prescription were included in the analysis. Costs and outcomes were 
discounted at 4% per annum. Costs of complications were taken from published 
sources. Results: A cohort of 605 T1DM patients (43% male) was analyzed. Mean 
age at first visit was 58 years, HbA1c was 7.8%, SBP was 132 mmHg, and BMI was 28 
kg/m2. Smokers represented 23% of the cohort. Results from economic modeling 
using the CDM suggest that for prevalent T1DM patients in France, potential sav-
ings for the health care system associated with meeting the therapeutic guidelines 
would be on average of 1,661 EUR per patient from a lifetime perspective. Most of 
the savings would come from the prevention of renal complications. Any new com-
plication would be delayed by 2.4 months on average. cOnclusiOns: The “Haute 
Autorité de Santé” recommends that T1DM patients maintain their HbA1c lower 
than 7.5%, SBP lower than 130 mmHg, BMI lower than 25 kg/m2 and quit smoking. 
Our results showed that these recommendations were not strictly followed among 
T1DM patients in France. Better adherence to the T1DM guidelines would lead to 
cost savings in the French health care system and improved patient outcomes.
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HealtH economic evaluation of canagliflozin in tHe treatment of 
tyPe 2 DiaBetes mellitus in czecH rePuBlic
Troelsgaard A.1, Pitcher A.2, Veselá Š.3, Lovato E.2, Hemels M.1
1Janssen A/S, Birkerød, Denmark, 2IMS Health, London, UK, 3Janssen-Cilag Czech Republic, 
Prague, Czech Republic
Objectives: Canagliflozin is a novel drug for treatment of diabetes belonging 
to the drug class known as sodium glucose co-transporter-2 (SGLT2) inhibitors 
which method of action is insulin independent. Canagliflozin has been shown to 
not only reduce glucose levels, but also weight and blood pressure. The objective is 
to evaluate the cost-effectiveness of canagliflozin 100mg in dual therapy (add-on 
to metformin) compared to sitagliptin and glimepiride, in triple therapy (add-on 
to metformin and sulfonylurea) compared to sitagliptin and as an insulin add-on 
compared to dapagliflozin in the Czech Republic setting from a payer perspec-
tive. MethOds: The IMS CORE Diabetes Model was used to evaluate the cost-
effectiveness of canagliflozin using clinical trial data and network meta-analysis 
data, combined with Czech Republic specific data, where available. Results: The 
cost-effectiveness analyses indicate that in dual therapy when compared with 
sitagliptin and glimepiride, canagliflozin 100mg is found to be cost-effective with 
an incremental cost-effectiveness ratio (ICER) of 242,783 Kč per QALY gained and 
626,939 Kč per QALY gained, respectively. In triple therapy when compared to sit-
agliptin, canagliflozin 100mg is found to be cost-effective with an ICER of 335,759 
Kč per QALY gained. As an add-on to insulin (with or without metformin), canagli-
flozin compared to dapagliflozin appears to be cost-effective with an ICER of 375 Kč 
per QALY gained. A wide range of deterministic sensitivity analyses revealed that 
in the majority of scenarios, canagliflozin remained cost-effective with ICERs well 
below the willingness-to-pay threshold of 1,100,000 Kč per QALY. cOnclusiOns: 
Canagliflozin 100mg represents a cost-effective option for the treatment of type 2 
diabetes in the Czech Republic. Canagliflozin 100mg offers greater health benefits 
than the included alternatives in this study, at a cost that provides good value 
for money.
pharmaceutical and blood glucose reagent strips. All measurements were obtained 
at individual level. Results: The raw prevalence of diabetes was 6.7%. All patients 
were stratified into four morbitity groups. The first group corresponded to the ini-
tial state (CRG 1-4); the second group included the core multimorbidity patients in 
the intermediate and advanced stages (CRG 5-7); the third group included patients 
with diabetes and malignancies; the last group was of patients with catastrophic 
statuses, manly ERSD. The most common comorbitities in the patient group for 
CRG 5 to 7 were hypertension (47% - 97%), dislipemia (50.9% - 59%) and cardiovas-
cular disease (18% - 39.9%). The average cost of insulin was € 117.1. The average 
cost of oral antidiabetic agents secretagogues was € 15.2 and was highest in the 
CRG 5 to 7 group at € 16.3. The average cost of non-secretagogue oral antidiabetic 
agents was € 212.9 and was highest in the CRG 5 to 7 group at € 232.8. The total 
average cost was € 476.5 in CRG 1-4 group, € 1350.5 in CRG 5-7 group, € 2174.1 in 
CRG 8 group and € 2840.5 in CRG 9 group. cOnclusiOns: Diabetes is charac-
terised by a strong presence of other chronic conditions and events related to 
its development throughout life. This multimorbidity has a great impact on the 
pharmaceutical cost.
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imPact of early microBiologic culture in tHe economic BurDen of 
care for Patients witH infecteD DiaBetic foot ulcers at a moDel of 
seconDary level imss’ HosPitals in mexico
Balderas-Peña L.M.A.1, Sat-Muñoz D.2, Alvarado-Iñiguez M.R.3, Salcedo-Rocha A.L.4,  
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Chagollán-Ramírez J.M.3, Prieto-Miranda S.E.5, García de Alba-García J.E.4
1UMAE Hospital de Especialidades Centro Médico Nacional de Occidente IMSS, Guadalajara, 
Jalisco, Mexico, 2UMAE Hospital de Gineco-Obstetricia Centro Médico Nacional de Occidente 
IMSS, Guadalajara, Jalisco, Mexico, 3Centro Universitario de Ciencias Económico Administrativas. 
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Guadalajara,, Mexico, 6Universidad de Guadalajara, Centro Universitario de Ciencias Exactas e 
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Objectives: Estimate the economic impact of the early microbiological culture 
in the cost-reduction associated to the attendance process of the infected ulcers 
in diabetic foot through an economic model based on a Monte Carlo simula-
tion. MethOds: Economic model of Monte Carlo simulation in two steps: The 
first step was a descriptive and longitudinal study. Were included diabetic subjects 
with infected ulcers in diabetic foot, patients were initially treated in Emergency 
Room of Mexican IMSS’ secondary level hospital in a period from January 1st to 
April 30th2010. Results: Micro-costing Analysis Results: Total costs for the sample 
were $502,438.04 USD, the mean cost per patient was $7,177.69 (±$5,043.51) USD, 
the median cost was $6,422.99 (p25 $3,502.93; p75 $9,298.33). 72.75% ($365,527.45) 
of the total cost was related to hospital stay. 10.6% ($53,240.86) of the expenditure 
during treatment was associated to wound healing care, 9.98% ($50,132.94) surger-
ies, 1.87% ($9,389.27), anti-diabetic drugs and concomitant chronic diseases. 1.79% 
($9,008.47) to clinical chemistry tests, 1% ($5,405.98) antibiotics, similar percentage 
to the imaging studies ($5,000.08), 0.66% ($3,309.88) acute phase reactants, 0.19% 
($965.65) microbiologic cultures, and the lowest percentage was destined to intra-
venous fluids. Monte carlo Modelling Results: Antibiotic cost analysis showed: If 
the physician takes a secretion sample in the first 48 hours of the patient admission 
in emergency room and begin the empirical antibiotic treatment, and modifies the 
criteria according microbiological results from the culture, the cost will be reduced 
(through antibiotic expenditure) 9 to 15%. The reduction could be 20 to 32% associ-
ated to reduce the hospital stay days. The total cost for the attendance process could 
be reduced 10 to 25%. cOnclusiOns: According Monte Carlo Modelling results the 
early microbiological culture as the base of antibiotic selection can reduce treat-
ment cost in more than 30%.
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Direct costs of DiaBetic foot ulcers in russia
Ignatyeva V.1, Avxentyeva M.1, Galstyan G.R.2, Bregovskiy V.3, Udovichenko O.4
1The Russian Presidential Academy of National Economy and Public Administration, Moscow, 
Russia, 2The Endocrinological Scientific Center, Moscow, Russia, 3Federal Almazov Medical 
Research Center, St. Petersburg, Russia, 4Moscow Municipal Outpatient Clinic #22, Moscow, Russia
Objectives: To evaluate the outcomes and current costs of 4 different sce-
narios of diabetic foot ulcers (DFU) treatment in Russian current medical prac-
tice. MethOds: We developed a decision tree model estimating annual number 
of outcomes (major and minor amputations) and costs for 4 simplified possible 
scenarios of medical care: 1) outpatient diabetic foot clinic, 2) non-specialized 
outpatient care, 3) cessation of the outpatient treatment by patient after the sec-
ond visit and 4) care provided only at hospital (without previous visits to any 
outpatient clinic). The distribution of the patient cohort (1000 patients) among the 
scenarios and rates of possible events were based on published Russian data and 
experts’ survey. Costs were calculated from the overall governmental budget point 
of view and included inpatient and outpatient care for DFU treatment, total con-
tact casting, medications and dressings provided in the outpatient care, prosthetic 
devices and services. Cost data was derived from published retrospective study 
comparing provision of care to DFU patients in specialized and non-specialized 
clinics in Russia and reimbursement rates in public medical insurance and social 
care. Results: The lowest rate of amputations per patient (0.07 for minor and 0.01 
for major) is expected for those receiving treatment in the outpatient diabetic foot 
clinic with mean annual cost € 279.68 per patient. The highest costs (€ 1141.17) and 
amputation rates (0.29 for minor and 0.19 for major) per patient are observed in 
the group treated at hospital only. The minor amputation rate and annual costs are 
higher for patients following non-specialized outpatient care than for those ceas-
ing the outpatient treatment – 0.11 vs 0.09 and € 449.82 vs € 381.30, and the reverse 
was observed for the rate of major amputations - 0.03 vs 0.06. cOnclusiOns: 
Referring DFU patients to the outpatient diabetic foot clinics as early as possible 
appears to be the most cost-effective way of treating them.
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infant in comparison to no-screening strategy. Transferred to the entire birth cohort 
newborn screening is able to reduce total costs by 14 million € from the Austrian 
health care systems perspective each year. cOnclusiOns: Funding the new-born 
screening saves money and is cost-effective for the Austrian health care system.
PDB66
tHe imPact of long-term clinical eviDence on cost-effectiveness 
of exenatiDe once weekly (ByDureon®) versus insulin glargine 
for Patients witH tyPe 2 DiaBetes mellitus (t2Dm) from a uk nHs 
PersPective
Charokopou M.1, Vioix H.2, Verheggen B.G.1, Bratt T.2, Franks D.2
1Pharmerit International, Rotterdam, The Netherlands, 2AstraZeneca UK Ltd., Luton, UK
Objectives: When patients start their first injectable therapy, clinicians can choose 
between glucagon-like peptide-1 (GLP-1) agonists and basal insulins. This study 
investigates the cost-effectiveness of exenatide once weekly (Bydureon®), a GLP-1 
agonist, compared with insulin glargine in patients inadequately controlled with 
metformin (±sulfonylureas) based on long-term clinical evidence. MethOds: The 
validated CARDIFF model was used to conduct the analyses. Clinical inputs were 
derived from a randomized clinical trial and a 3-year follow-up study of it comparing 
exenatide once weekly (ExQW) versus insulin glargine once daily. Based on these clini-
cal inputs and the United Kingdom Prospective Diabetes Study (UKPDS) equations, 
the model predicts disease progression and the number of micro- and macro-vascular 
complications, along with diabetes-specific and all-cause mortality. The perspective 
of the National Health Service in the UK was adopted over a lifetime horizon. Local 
unit costs and utility data were assigned to the appropriate model parameters to 
calculate total Quality-Adjusted-Life-Years (QALYs) and total costs. Deterministic 
and probabilistic sensitivity analyses (PSA) were conducted. Results: Long-term 
treatment with ExQW was well tolerated and associated with sustained glycaemic 
control and sustained weight loss over at least 3 years. Compared to glargine, ExQW 
in combination with metformin was associated with an incremental benefit of 0.123 
QALYs (95%CI: 0.057; 0.178) at an additional cost of £1,722 (95%CI: £1,396; £2,089), 
resulting in an incremental cost-effectiveness ratio of £13,967 per QALY gained. The 
PSA showed that at a willingness-to-pay threshold of £20,000 per QALY gained, ExQW 
treatment had an 83% probability to be cost-effective compared to the strategy includ-
ing glargine. Sensitivity analyses showed that results were robust to variation in 
model parameters that carry uncertainty. cOnclusiOns: Exenatide once weekly in 
combination with metformin was shown to be a cost-effective treatment option as 
first injectable therapy in patients inadequately controlled with metformin within 
established UK cost-effectiveness thresholds.
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DaPagliflozin (forxiga®) versus gliPiziDe as aDD-on tHeraPies in 
tyPe 2 DiaBetes mellitus (t2Dm); an uPDate of tHe cost-effectiveness 
BaseD on long-term clinical eviDence from uk nHs PersPective
Charokopou M.1, Vioix H.2, Verheggen B.G.1, Dillon S.2, Franks D.2
1Pharmerit International, Rotterdam, The Netherlands, 2AstraZeneca UK Ltd., Luton, UK
Objectives: To update the cost-effectiveness of dapagliflozin (Forxiga®), a selective 
sodium-glucose co-transporter-2 (SGLT-2) inhibitor, compared with a sulphonylurea 
(SU) when added to metformin in patients inadequately controlled with metformin 
mono-therapy based on long-term clinical evidence. MethOds: The published 
and validated CARDIFF diabetes model was used to conduct the analyses. Clinical 
inputs were derived from a 4-year follow-up study of a randomized clinical trial 
comparing dapagliflozin and glipizide in combination with metformin. Based on 
these clinical inputs and the United Kingdom Prospective Diabetes Study (UKPDS) 
equations, the model predicts disease progression and the number of micro- and 
macro-vascular complications, along with diabetes-specific and all-cause mor-
tality. The perspective of the National Health Service in England and Wales was 
adopted over a lifetime horizon. Local unit costs and utility data were assigned to 
the appropriate model parameters to calculate total Quality-Adjusted-Life-Years 
(QALYs) and total costs. Deterministic and probabilistic sensitivity analyses (PSA) 
were conducted. Results: Dapagliflozin showed greater durability of HbA1c reduc-
tion compared with SU and sustained weight loss over 4 years. Compared to SU 
added on top of metformin, dapagliflozin add-on to metformin was associated with 
an incremental benefit of 0.181 QALYs (95%CI: 0.088; 0.268) at an additional cost of 
£819 (95%CI: £415; £1,259), resulting in an ICER point estimate of £4,521 per QALY 
gained. The univariate analyses showed that no input parameter change inflated the 
ICER above £15,000 per QALY. The PSA showed that at a willingness-to-pay threshold 
of £20,000 per QALY gained, dapagliflozin treatment had an estimated 100% prob-
ability to be cost-effective compared to an SU treatment strategy. These findings 
were shown to be robust with all sensitivity analyses. cOnclusiOns: Dapagliflozin 
in combination with metformin was shown to be a cost-effective treatment option 
for patients who are inadequately controlled with metformin mono-therapy within 
established UK cost-effectiveness thresholds.
PDB68
HealtH economic evaluation of canagliflozin in tHe treatment of 
tyPe 2 DiaBetes mellitus in Portugal
Troelsgaard A.1, Knudsen M.2, Maia-Lopes S.3, Luz M.3, Hemels M.1
1Janssen A/S, Birkerød, Denmark, 2IMS Health, Hellerup, Denmark, 3Janssen-Cilag Farmacêutica, 
Barcarena, Portugal
Objectives: To evaluate the cost-effectiveness of canagliflozin in dual therapy as 
add-on to metformin compared to sitagliptin and in triple therapy as add-on to met-
formin (MET) and sulfonylurea (SU) compared to sitagliptin. MethOds: The IMS 
CORE Diabetes Model was used to evaluate the cost-effectiveness of canagliflozin 
100 mg and 300 mg versus sitagliptin 100 mg using data from both clinical trials and 
network meta-analysis, combined with Portuguese-specific data when available. The 
perspective of the analysis is societal in accordance with Guidelines for Economic 
Drug Evaluation Studies from INFARMED. Results: The cost-effectiveness analyses 
indicate that canagliflozin (100 mg and 300 mg weighted average 65: 35) is cost-saving 
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sHort-term cost-effectiveness analysis of insulin Detemir versus 
insulin neutral Protamine HageDorn (nPH) in Patients witH tyPe 2 
DiaBetes mellitus in sPain
Ramírez de Arellano A.1, Morales C.2, De Luis D.3, Ferrario M.G.4, Lizán L.5
1Novo Nordisk Pharma SA, Madrid, Spain, 2Hospital Virgen de la Macarena, Sevilla, Spain, 
3Hospital Rio Hortega, Valladolid, Spain, 4Outcomes’10, Castellon, Spain, 5Outcomes 10,  
Castellon, Spain
Objectives: To estimate the short-term cost-effectiveness of insulin detemir 
compared with Neutral Protamine Hagedorn (NPH) insulin when initiating insulin 
treatment in patients with Type 2 Diabetes Mellitus (T2DM) in Spain. MethOds: A 
short-term (1 year) cost-effectiveness model was adapted to the Spanish public health 
care system. Based on a head-to-head randomized controlled trial (NCT00104182) 
that showed similar efficacy in glycemic control for both insulin types, weight gain 
(Δ = 0.9Kg) and the rate of non-severe hypoglycemia (between-arms RR= 0.52; IC95% 
0.44-0.61) of detemir vs. NPH were selected as clinical outcomes. Costs (Euros 2014) 
were estimated from the perspective of the Spanish national health system and 
derived from national public sources. Only insulin treatment and management costs 
associated with non-severe hypoglycemic episodes were included in the analysis. 
According to a published study, non-severe hypoglycemia (a self-managed event) 
was assumed to imply the use of 5.3 glucometer strips and a visit to a general practi-
tioner for 25% of patients (Orozco-Beltrán et al., 2014). The disutility value associated 
to weight gain was -0.0100 per BMI unit (Lee et al., 2005). The disutility associated to 
daytime and nocturnal non-severe hypoglycemia was -0.0041 and -0.0067 per event, 
respectively (Evans et al., 2013). Results: The yearly gain in quality-adjusted life 
years (QALY) associated to insulin detemir versus NPH was 0.015. The estimated 
incremental cost of treating patients with insulin detemir versus NPH was € 244.03. 
The incremental cost-effectiveness ratio (ICER) of insulin detemir versus NPH in 
insulin-naïve T2DM patients was estimated to be € 16,381.18/QALY in Spain. This 
value is lower than those published for other European countries (€ 21,768-28,349/
QALY) and is beneath the ICER threshold commonly accepted for Spain (€ 30,000/
QALY). cOnclusiOns: Insulin detemir is a cost-effective alternative to NPH insulin in 
the first and subsequent years of treatment of insulin-naïve T2DM patients in Spain.
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cost-effectiveness analysis of insulin Detemir versus insulin 
neutral Protamine HageDorn (nPH) in Patients witH tyPe 1 DiaBetes 
mellitus in sPain
Ramírez de Arellano A.1, Lizán L.2, Prades M.2, Morales C.3, De Luis D.4
1Novo Nordisk Pharma SA, Madrid, Spain, 2Outcomes 10, Castellon, Spain, 3Hospital Virgen de la 
Macarena, Sevilla, Spain, 4Hospital Rio Hortega, Valladolid, Spain
Objectives: To estimate the short-term cost-effectiveness of insulin detemir 
compared with Neutral Protamine Hagedorn (NPH) insulin when initiating insulin 
treatment in patients with Type 1 Diabetes Mellitus (T1DM) in Spain. MethOds: A 
short-term (1 year) cost-effectiveness model was adapted to the Spanish public health 
care system. Based on the Update of CADTH Technology Report No. 92 (2008) that 
showed similar efficacy in glycemic control for both insulin types, the rate of hypo-
glycemia with detemir vs. NPH (RR= 0.84; IC95% 0.74-0.97) was the considered clinical 
outcome. Costs, expressed in Euros 2014, were estimated from the perspective of the 
Spanish national health system and derived from national health care cost databases 
and publications. Only insulin treatment and management costs associated with 
non-severe hypoglycemic episodes were included in the analysis. Non-severe hypo-
glycemia, defined as a self-managed event, was assumed to imply the use of extra 5.3 
glucometer strips during the following week and a visit to a general practitioner for 
25% of patients (Orozco-Beltrán et al., 2014). The disutility associated to daytime and 
nocturnal non-severe hypoglycemia was -0.0041 and -0.0067 per event, respectively 
(Evans et al., 2013). Results: The gain in quality-adjusted life years (QALY) associated 
to determir versus NPH was 0.108. The estimated incremental cost of determir versus 
NPH was € 247.40. The incremental cost-effectiveness ratio (ICER) of detemir vs. NPH 
in patients with T1DM was estimated to be € 2,286.67/QALY in Spain. This value is 
significantly lower than those reported for other European countries (€ 10,938-13,310/
QALY) and are much lower than the ICER threshold commonly accepted for Spain 
(€ 30,000/QALY). cOnclusiOns: Detemir is a cost-effective alternative to NPH insulin 
in the first year of treatment of insulin-naive T1DM patients in Spain.
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cost-effectiveness-analysis of tHe new-Born screening in austria
Walter E.1, Kasper D.C.2
1Institute for Pharmaeconomic Research, Vienna, Austria, 2Department of Pediatrics and 
Adolescent Medicine, Vienna, Austria
Objectives: Since more than 45 years, a preventive program for the detection of 
congenital metabolic and endocrine diseases is carried out successfully in Austria. The 
goal is to investigate every new-born a few days after birth to initiate a quality assured 
therapy as quickly as possible. Since 1966, this program is carried out by the Federal 
Ministry of Health at the University Clinic for Child and Adolescent Medicine, Medical 
University of Vienna. The aim of this study was to determine cost-effectiveness of 
the new-born screening. MethOds: We developed a decision-analytic model, which 
include specific Markov processes for the core disorders: Cystic Fibrosis (CF), phe-
nylketonuria (PKU), medium-chain acyl-CoA (MCAD), congenital hypothyroidism (CH), 
galactosemia (GAL) and Maple syrup urine disease (MSUD). Costs and health benefits 
were estimated for a cohort of new-borns in Austria in 1 year. The analysis focused 
on lifetime consequences. This encompassed direct costs (including screening costs 
and cost of illness), quality-adjusted-life-years (QALYs) and reduced expectation of 
life. Costs were presented per child and for the Austrian birth cohort. Costs from 
published sources were used (2014 Euro) from the health care systems perspective. 
QALYs, life-years (LYs) and costs were projected over a life-time horizon and dis-
counted at 3% p. a. Results: We found ten-times higher lifetime costs per child 
without screening compared to screening. The incremental costs of screening ranged 
from 12.308 € (MCAD) to 291.332 € (PKU). Screening saved 181 € and 0.09 QALYs per 
